GlassScriptPhysician profile
Ellen Mary Mccalla
NPI 1548012255
$503.98
in general payments reported to CMS, 2019-2025
13 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $199 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $139.14 | 2025 | Ozempic, Wegovy |
| Lundbeck LLC | $57.75 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $50.19 | 2024-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $46.79 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $46.13 | 2024 | Fanapt, Hetlioz |
| Convatec INC. | $30.21 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.33 | 2025 | Horizant |
| Noven Therapeutics, LLC | $22.80 | 2025 | Secuado |
| Indivior INC. | $21.20 | 2025 | Sublocade |
| Lilly USA, LLC | $20.28 | 2024 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.79 | 2024 | Caplyta |
| Amgen INC. | $14.85 | 2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $13.52 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Mccalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.